The role of Akt-GSK-3β signaling and synaptic strength in phencyclidine-induced neurodegeneration

Neuropsychopharmacology

Volumn 33, Issue 6, 2008, Pages 1343-1353

  Lei, Gang ^a   Xia, Yan ^a   Johnson, Kenneth M ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Akt; Glycogen synthase kinase 3 ; Neurotoxicity; NMDA receptor; Phencyclidine; Schizophrenia

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; CALCIUM CHANNEL L TYPE; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SYNAPTIC POTENTIAL; WESTERN BLOTTING;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ANIMALS; CALCIUM CHANNEL AGONISTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO, MAMMALIAN; FEMALE; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; L-LACTATE DEHYDROGENASE; NERVE DEGENERATION; ONCOGENE PROTEIN V-AKT; PHENCYCLIDINE; PREGNANCY; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SYNAPSES; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS;

EID: 42049091873     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301511     Document Type: Article

References (77)

1. Ahn YM, Seo MS, Kim SH, Kim Y, Yoon SC, Juhnn YS et al (2005). Increased phosphorylation of Ser473-Akt, Ser9-GSK-3beta and Ser133-CREB in the rat frontal cortex after MK-801 intraperitoneal injection. Int J Neuropsychopharmacol 8: 607-613.
2. Alagarsamy S, Phillips M, Pappas T, Johnson KM (1997). Dopamine neurotoxicity in cortical neurons. Drug Alcohol Depend 48: 105-111.
3. Anis NA, Berry SC, Burton NR, Lodge D (1983). The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate. Br J Pharmacol 79: 565-575.
4. Bain J, McLauchlan H, Elliott M, Cohen P (2003). The specificities of protein kinase inhibitors: an update. Biochem J 371: 199-204.
5. Bajestan SN, Sabouri AH, Nakamura M, Takashima H, Keikhaee MR, Behdani F et al (2006). Association of AKT1 haplotype with the risk of schizophrenia in Iranian population. Am J Med Genet B Neuropsychiatr Genet 141: 383-386.
6. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR et al (2004). Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 101: 5099-5104.
7. Bijur GN, Jope RS (2001). Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 276: 37436-37442.
8. Blair LA, Marshall J (1997). IGF-1 modulates N and L calcium channels in a PI 3-kinase-dependent manner. Neuron 19: 421-429.
9. Brami-Cherrier K, Valjent E, Garcia M, Pages C, Hipskind RA, Caboche J (2002). Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J Neurosci 22: 8911-8921.
10. Brazil DP, Yang ZZ, Hemmings BA (2004). Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29: 233-242.
11. Canzoniero LM, Babcock DJ, Gottron FJ, Grabb MC, Manzerra P, Snider BJ et al (2004). Raising intracellular calcium attenuates neuronal apoptosis triggered by staurosporine or oxygen-glucose deprivation in the presence of glutamate receptor blockade. Neurobiol Dis 15: 520-528.
12. Cohen P, Frame S (2001). The renaissance of GSK-3. Nat Rev Mol Cell Biol 2: 769-776.
13. Cohen P, Goedert M (2004). GSK-3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3: 479-487.
14. Coyle JT (2006). Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26: 363-382.
15. Datta SR, Brunet A, Greenberg ME (1999). Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
16. Davies SP, Reddy H, Caivano M, Cohen P (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
17. Dolmetsch RE, Pajvani U, Fife K, Spotts JM, Greenberg ME (2001). Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase pathway. Science 294: 333-339.
18. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004). Convergent evidence for impaired AKT1-GSK-3beta signaling in schizophrenia. Nat Genet 36: 131-137.
19. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H et al (1995). Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry 38: 788-796.
20. Filippa N, Sable CL, Filloux C, Hemmings B, Van Obberghen E (1999). Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol Cell Biol 19: 4989-5000.
21. Gomez-Ospina N, Tsuruta F, Barreto-Chang O, Hu L, Dolmetsch R (2006). The C terminus of the L-type voltage-gated calcium channel Ca(V)1.2 encodes a transcription factor. Cell 127: 591-606.
22. Graef IA, Mermelstein PG, Stankunas K, Neilson JR, Deisseroth K, Tsien RW et al (1999). L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature 401: 703-708.
23. Han KS, Kang HJ, Kim EY, Yoon WJ, Sohn S, Kwon HJ et al (2001). 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid induces caspase-mediated apoptosis and reactive oxygen species-mediated necrosis in cultured cortical neurons. J Neurochem 78: 230-239.
24. Hansen HH, Briem T, Dzietko M, Sifringer M, Voss A, Rzeski W et al (2004). Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol Dis 16: 440-453.
25. Hardingham GE, Fukunaga Y, Bading H (2002). Extrasynaptic NMDA receptors oppose synaptic NMDA receptors by triggering CREB shut-off and cell death pathways. Nat Neurosci 5: 405-414.
26. Hetman M, Hsuan SL, Habas A, Higgins MJ, Xia Z (2002). ERK1/2 antagonizes glycogen synthase kinase-3beta-induced apoptosis in cortical neurons. J Biol Chem 277: 49577-49584.
27. Hwang JY, Kim YH, Ahn YH, Wie MB, Koh JY (1999). N-methyl- D-aspartate receptor blockade induces neuronal apoptosis in cortical culture. Exp Neurol 159: 124-130.
28. Ide M, Ohnishi T, Murayama M, Matsumoto I, Yamada K, Iwayama Y et al (2006). Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia. J Neurochem 99: 277-287.
29. Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y et al (2004). Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry 56: 698-700.
30. Ikegami K, Koike T (2000). Membrane depolarization-mediated survival of sympathetic neurons occurs through both phosphatidylinositol 3-kinase- and CaM kinase II-dependent pathways. Brain Res 866: 218-226.
31. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K et al (1999). Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283: 70-74.
32. Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben Ari Y et al (2006). Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol 572: 789-798.
33. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY et al (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137.
34. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225.
35. Johnson KM, Jones SM (1990). Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30: 707-750.
36. Jope RS, Johnson GV (2004). The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102.
37. Jope RS, Roh MS (2006). Glycogen synthase kinase-3 (GSK-3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 7: 1421-1434.
38. Kalkman HO (2006). The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacol Ther 110: 117-134.
39. Kozlovsky N, Belmaker RH, Agam G (2002). GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol 12: 13-25.
40. Kozlovsky N, Nadri C, Agam G (2005). Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Eur Neuropsychopharmacol 15: 1-11.
41. Kozlovsky N, Amar S, Belmaker RH, Agam G (2006). Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol 9: 337-342.
42. Kumar CC, Madison V (2005). AKT crystal structure and AKT-specific inhibitors. Oncogene 24: 7493-7501.
43. Lai WS, Xu B, Westphal KG, Paterlini M, Olivier B, Pavlidis P et al (2006). Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci USA 103: 16906-16911.
44. Lewis DA, Gonzalez-Burgos G (2006). Pathophysiologically based treatment interventions in schizophrenia. Nat Med 12: 1016-1022.
45. Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA et al (2004). Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 24: 9993-10002.
46. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME (1999). Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286: 785-790.
47. Marshall J, Dolan BM, Garcia EP, Sathe S, Tang X, Mao Z et al (2003). Calcium channel and NMDA receptor activities differentially regulate nuclear C/EBPbeta levels to control neuronal survival. Neuron 39: 625-639.
48. Morgan JI, Curran T (1986). Role of ion flux in the control of c-fos expression. Nature 322: 552-555.
49. Morris BJ, Cochran SM, Pratt JA (2005). PCP: from pharmacology to modeling schizophrenia. Curr Opin Pharmacol 5: 101-106.
50. Murphy TH, Worley PF, Baraban JM (1991). L-type voltage-sensitive calcium channels mediate synaptic activation of immediate early genes. Neuron 7: 625-635.
51. Norton N, Williams HJ, Owen MJ (2006). An update on the genetics of schizophrenia. Curr Opin Psychiatry 19: 158-164.
52. Ohtsuki T, Inada T, Arinami T (2004). Failure to confirm association between AKT1 haplotype and schizophrenia in a Japanese case-control population. Mol Psychiatry 9: 981-983.
53. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007.
54. 2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci 25: 4279-4287.
55. Rivero Vaccari JC, Casey GP, Aleem S, Park WM, Corriveau RA (2006). NMDA receptors promote survival in somatosensory relay nuclei by inhibiting Bax-dependent developmental cell death. Proc Natl Acad Sci USA 103: 16971-16976.
56. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT (2006). Neurobiology of schizophrenia. Neuron 52: 139-153.
57. Rothman RB, Reid AA, Monn JA, Jacobson AE, Rice KC (1989). The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites. Mol Pharmacol 36: 887-896.
58. Schwab SG, Hoefgen B, Hanses C, Hassenbach MB, Albus M, Lerer B et al (2005). Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry 58: 446-450.
59. Seeman P, Ko F, Tallerico T (2005). Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10: 877-883.
60. Seeman P, Lasaga M (2005). Dopamine agonist action of phencyclidine. Synapse 58: 275-277.
61. Shelnutt SR, Gunnell M, Owens SM (1999). Sexual dimorphism in vitro metabolism and pharmacokinetics in rats. J Pharmacol Exp Ther 290: 1292-1298.
62. Song L, De Sarno P, Jope RS (2002). Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 277: 44701-44708.
63. Soriano FX, Papadia S, Hofmann F, Hardingham NR, Bading H, Hardingham GE (2006). Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci 26: 4509-4518.
64. Sutton G, Chandler LJ (2002). Activity-dependent NMDA receptor-mediated activation of protein kinase B/Akt in cortical neuronal cultures. J Neurochem 82: 1097-1105.
65. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M et al (2003). Diverse psychotomimetics act through a common signaling pathway. Science 302: 1412-1415.
66. Szatmari E, Habas A, Yang P, Zheng JJ, Hagg T, Hetman M (2005). A positive feedback loop between glycogen synthase kinase 3beta and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons. J Biol Chem 280: 37526-37535.
67. Takadera T, Matsuda I, Ohyashiki T (1999). Apoptotic cell death and caspase-3 activation induced by N-methyl-D-aspartate receptor antagonists and their prevention by insulin-like growth factor I. J Neurochem 73: 548-556.
68. Takadera T, Ishida A, Ohyashiki T (2006). Ketamine-induced apoptosis in cultured rat cortical neurons. Toxicol Appl Pharmacol 210: 100-107.
69. Turner CP, Pulciani D, Rivkees SA (2002). Reduction in intracellular calcium levels induces injury in developing neurons. Exp Neurol 178: 21-32.
70. Vanhoutte P, Bading H (2003). Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signaling and BDNF gene regulation. Curr Opin Neurobiol 13: 366-371.
71. Wang C, Fridley J, Johnson KM (2005). The role of NMDA receptor upregulation in phencyclidine-induced cortical apoptosis in organotypic culture. Biochem Pharmacol 69: 1373-1383.
72. Wang C, Kaufmann JA, Sanchez-Ross MG, Johnson KM (2000). Mechanisms of N-methyl-D-aspartate-induced apoptosis in phencyclidine-treated cultured forebrain neurons. J Pharmacol Exp Ther 294: 287-295.
73. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM (2001). Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107: 535-550.
74. Wang CZ, Johnson KM (2005). Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J Neurosci Res 81: 284-292.
75. Wang CZ, Johnson KM (2007). The role of caspase-3 activation in phencyclidine-induced neuronal death in postnatal rats. Neuropsychopharmacology 32: 1178-1194.
76. Yano S, Morioka M, Kuratsu J, Fukunaga K (2005). Functional proteins involved in regulation of intracellular Ca(2+) for drug development: role of calcium/calmodulin-dependent protein kinases in ischemic neuronal death. J Pharmacol Sci 97: 351-354.
77. 2+ deficiency. J Neurochem 85: 525-533.